Kinetics of Maternally Derived Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Infants in Relation to the Timing of Antenatal Vaccination.

Rottenstreich, Amihai; Zarbiv, Gila; Oiknine-Djian, Esther; Vorontsov, Olesya; Zigron, Roy; Kleinstern, Geffen; Porat, Shay; Wolf, Dana G

Background SARS-CoV-2 infection during early infancy can result in severe disease. We evaluated the durability of maternally-derived anti-SARS-CoV-2 antibodies in infants and its relation to antenatal vaccination timing. Methods Sera were prospectively collected at birth and 3 months after delivery from mother-infant pairs following antenatal BNT162b2 vaccination. SARS-CoV-2 receptor binding domain (RBD)-specific IgG levels and neutralizing activity were evaluated. Results 56 mother-infant pairs were included: 15 (26.8%) were vaccinated in the first trimester, 16 (28.6%) in the second trimester, and 25 (44.6%) in the third trimester. At the time of delivery, all neonates were positive for anti-RBD-specific IgG with a median concentration of 4046 [IQR 2446–7896] AU/mL, with the highest concentration found after third trimester vaccination (median 6763 [IQR 3857–12561] AU/mL). At 3 months after delivery, anti RBD-specific IgG levels in infants significantly waned with a median concentration of 545 [IQR 344–810] AU/mL (P <.001). The half-life of anti-RBD-specific IgG was 66 days among mothers and 30 days among infants. While at the time of delivery, all neonates had detectable neutralizing activity regardless of gestational age at vaccination, at 3-months of age, a higher proportion of infants born to mothers vaccinated in third trimester had persistent neutralizing activity as compared to those born to mothers vaccinated in second trimester. Conclusions Maternal vaccination leads to efficient transplacental antibody transfer, with persistent anti-SARS-CoV-2 antibodies detected at 3 months of age in all infants. The observed effect of antenatal immunization timing on the kinetics of maternally-derived antibodies may have implications for SARS-CoV-2 vaccination strategies.

IMMUNOGLOBULIN analysis; COVID-19; IMMUNIZATION; IMMUNOGLOBULINS; MATERNAL-fetal exchange; COVID-19 vaccines; CELL receptors; MATERNALLY acquired immunity; DESCRIPTIVE statistics; LONGITUDINAL method; PREGNANCY

Clinical Infectious Diseases, 2023, Vol 76, Issue 3, pe274

1058-4838

Academic Journal

10.1093/cid/ciac480